Delmar Pharma (DMPI) 0.7000 $DMPI
DelMar Pharmaceuticals Announces December 31, 2014 Financial Results and Provides Corporate Update
PR Newswire - Thu Feb 12, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
today announced the filing of its financial statements for the six months ended December 31, 2014 and provided an overview of recent Company highlights and expected near-term milestones. Management will host an investor update conference call and live webcast to discuss recent highlights and the Company's plans for the continued advancement of its business plan on Tuesday, February 17, 2015, at 1:30 p.m. PST / 4:30 p.m. EST.
DelMar Pharmaceuticals names Lynda Cranston to board
M2 - Thu Feb 12, 6:41AM CST
Cancer therapies company DelMar Pharmaceuticals (OtherOTC
MPI) said on Wednesday that Lynda Cranston, BScN, MScN, ICD.D, has been elected as an independent director to its board of directors.
DelMar Pharmaceuticals Appoints Lynda Cranston, BScN, MScN, ICD.D, to the Board of Directors
PR Newswire - Wed Feb 11, 7:13AM CST
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company" , today announced that it has appointed Lynda Cranston, BScN, MScN, ICD.D, to its Board of Directors as an independent director. Ms. Cranston serves as Chair of the Company's newly formed Governance and Compensation Committee.
DelMar Pharmaceuticals Completes Offer to Exchange Common Stock for Outstanding Warrants
PR Newswire - Tue Feb 10, 8:35AM CST
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company" , today announced that it has completed a tender offer to exchange ("Offer to Exchange" new shares of the Company's common stock ("Shares" for outstanding Company warrants to purchase up to 5,964,738 shares of common stock (the "Warrants" (at a ratio of one Share for every three Warrants tendered). Upon expiry of the Offer to Exchange, 1,591,875 Warrants were exchanged, and the Company will issue 530,625 new shares of common stock.
DelMar Pharmaceuticals awarded notice of allowance for third US patent for VAL-083, expanding to three US patents and one international patent
M2 - Wed Jan 14, 6:54AM CST
Cancer therapies company DelMar Pharmaceuticals (Other OTC MPI) reported on Tuesday the receipt of the US Patent and Trademark Office's (USPTO) notice of allowance for patent application number 14/083,135, entitled, "Analytical Method for Analyzing and Determining Impurities in Dianhydrogalactitol (VAL-083)".
DelMar Pharmaceuticals Receives Notice of Allowance for Third US Patent for VAL-083
PR Newswire - Tue Jan 13, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar", "the Company" today announced that the U.S. Patent and Trademark Office (USPTO) has issued a notice of allowance for patent application number 14/083,135, entitled, "Analytical Method for Analyzing and Determining Impurities in Dianhydrogalactitol (VAL-083)".
DelMar Pharmaceuticals Provides Update on VAL-083 Clinical Trial and Outlines Corporate Objectives for 2015
PR Newswire - Mon Jan 12, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar", "the Company) provided an update on the Company's ongoing Phase I/II clinical trial with VAL-083 as a potential new treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. In addition, DelMar outlined its corporate objectives for 2015.
DelMar Pharmaceuticals Commences Offer to Exchange Common Stock for Outstanding Warrants
PR Newswire - Thu Jan 08, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company", "we" or "our" today announced that it has commenced an offer to exchange ("Offer to Exchange" new shares of the Company's common stock ("Shares" for outstanding Company warrants to purchase up to 5,964,738 shares of common stock (the "Warrants" (at a ratio of one Share for every three Warrants tendered). In the event that all of the Warrants are exchanged, the Company shall issue 1,988,246 new shares of common stock.
DelMar Pharmaceuticals to Present at Biotech Showcase(TM) 2015
PR Newswire - Wed Jan 07, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar", the "Company" announced today that Jeffrey Bacha, DelMar's president & CEO, will be presenting at the Biotech Showcase(TM) 2015 Conference being held in San Francisco, CA.
Key Growth Opportunities:KSA InterviewsDelmar Pharmaceutical,Critical Control Solutions Corp andCemtrex, Inc.
Marketwired - Wed Dec 17, 12:00PM CST
Delmar Pharmaceutical's (OTCQX: DMPI) CEO Jeff Bacha took time to update listeners on the company's lead compound, VAL-083 and it's clinical applications. He talked about how VAL-083 is able to penetrate the elusive blood brain barrier and therefore has potential in treating Glioblastoma in patients that have failed first and second-line therapy. He added that this molecule is also approved in China for the treatment of lung cancer so Delmar has also been generating new preclinical data to reposition the product. Mr. Bacha elaborated on the company's key goals for the next 12 months, the main one being to complete dose escalation and advance into a registration directed trial, which will position them to file for an approval with the FDA regarding refractory Glioblastoma.
CCZ.TO: 0.30 (-0.01)
DelMar Pharmaceuticals Joins OTCQX
PR Newswire - Tue Dec 02, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and "DelMar Pharma" , a clinical stage drug development company focused on the development and commercialization of a new chemotherapy for the treatment of refractory glioblastoma multiforme (GBM), the most common and deadly form of human brain cancer, announced that it will begin trading today on the OTCQX® marketplace.
OTC Markets Group Welcomes DelMar Pharmaceuticals to OTCQX®
PR Newswire - Tue Dec 02, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced DelMar Pharmaceuticals, Inc. (OTCQX: DMPI), a clinical and commercial stage drug development company, has qualified to trade on OTCQX®, the best marketplace for established, global and growth companies.
SeeThruEquity Issues Update on DelMar Pharmaceuticals Highlighting New Data on VAL-083
ACCESSWIRE - Thu Nov 20, 8:33AM CST
New York, NY / ACCESSWIRE / November 20, 2014 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments.
DelMar Pharmaceuticals' Promising New Data Support the Potential of VAL-083 to Meet Significant Unmet Medical Needs in the Treatment of Glioblastoma Multiforme
PR Newswire - Mon Nov 17, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma" today announced the presentation of new data supporting the development of VAL-083 (dianhydrogalactitol), which is currently undergoing clinical development in the United States as a potential new chemotherapy for the treatment of refractory glioblastoma multiforme (GBM), the most common and deadly form of human brain cancer.
DelMar Pharmaceuticals Presents Preclinical Data Supporting VAL-083 as a Potential New Treatment in Glioblastoma at the Society of Neuro-Oncology Annual Meeting
PR Newswire - Fri Nov 14, 10:45AM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma" today announced the presentation of an abstract entitled, In vivo efficacy of VAL-083 in the treatment of MGMT-positive glioblastoma multiforme (GBM).
DelMar Pharmaceuticals Announces September 30, 2014 Results and Provides Corporate Update
PR Newswire - Mon Nov 10, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the company" today announced the filing of September 30, 2014 quarterly financial statements.
DelMar Pharmaceuticals Invited to Present New Data on VAL-083 in the Treatment of Glioblastoma Multiforme at the Society for NeuroOncology Annual Meeting
PR Newswire - Thu Nov 06, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma" today announced that the Company has been invited to present three separate abstracts at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology being held November 13 to 16 in Miami. The presentations will detail continued advancement and new understandings in the research and development of VAL-083, a potential new therapy for refractory glioblastoma multiforme (GBM), the most common and deadly form of brain cancer.
The Life Sciences Report Interviews SeeThruEquity Regarding Microcap Life Sciences Companies
ACCESSWIRE - Wed Nov 05, 8:24AM CST
New York, NY / ACCESSWIRE / November 5, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it was recently interviewed by The Life Sciences Report regarding the microcap market for life sciences companies, during which SeeThruEquity analysts discussed DelMar Pharmaceuticals Inc. (OTCQB: DMPI), Manhattan Scientifics Inc. (OTCQB: MHTX) and TapImmune Inc. (OTCQB: TPIV).
VAL-083 Demonstrates Promise as a Potential Treatment for Non-small Cell Lung Cancer
PR Newswire - Thu Oct 09, 7:44AM CDT
DelMar Pharmaceuticals, Inc., (OTCQB: DMPI), a clinical-stage oncology company, today announced the presentation of promising new data supporting the activity of its lead drug compound, VAL-083, in the treatment of non-small cell lung cancer (NSCLC) at the AACR's New Horizons in Cancer Research: Harnessing Breakthroughs - Targeting Cures. The conference takes place October 9th to 12th in Pudong, Shanghai.
DelMar Pharmaceuticals Announces Presentations at Upcoming Scientific Meetings
PR Newswire - Mon Oct 06, 10:47AM CDT
DelMar Pharmaceuticals, Inc., (OTCQB: DMPI), a clinical-stage oncology company, today announced that the company has been invited to present new advancements at two upcoming peer reviewed scientific meetings.
DelMar Pharmaceuticals Announces December 31, 2014 Financial Results and Provides Corporate Update
PR Newswire - Thu Feb 12, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
today announced the filing of its financial statements for the six months ended December 31, 2014 and provided an overview of recent Company highlights and expected near-term milestones. Management will host an investor update conference call and live webcast to discuss recent highlights and the Company's plans for the continued advancement of its business plan on Tuesday, February 17, 2015, at 1:30 p.m. PST / 4:30 p.m. EST. DelMar Pharmaceuticals names Lynda Cranston to board
M2 - Thu Feb 12, 6:41AM CST
Cancer therapies company DelMar Pharmaceuticals (OtherOTC
MPI) said on Wednesday that Lynda Cranston, BScN, MScN, ICD.D, has been elected as an independent director to its board of directors. DelMar Pharmaceuticals Appoints Lynda Cranston, BScN, MScN, ICD.D, to the Board of Directors
PR Newswire - Wed Feb 11, 7:13AM CST
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
, today announced that it has appointed Lynda Cranston, BScN, MScN, ICD.D, to its Board of Directors as an independent director. Ms. Cranston serves as Chair of the Company's newly formed Governance and Compensation Committee. DelMar Pharmaceuticals Completes Offer to Exchange Common Stock for Outstanding Warrants
PR Newswire - Tue Feb 10, 8:35AM CST
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"
, today announced that it has completed a tender offer to exchange ("Offer to Exchange" new shares of the Company's common stock ("Shares" for outstanding Company warrants to purchase up to 5,964,738 shares of common stock (the "Warrants" (at a ratio of one Share for every three Warrants tendered). Upon expiry of the Offer to Exchange, 1,591,875 Warrants were exchanged, and the Company will issue 530,625 new shares of common stock. DelMar Pharmaceuticals awarded notice of allowance for third US patent for VAL-083, expanding to three US patents and one international patent
M2 - Wed Jan 14, 6:54AM CST
Cancer therapies company DelMar Pharmaceuticals (Other OTC
MPI) reported on Tuesday the receipt of the US Patent and Trademark Office's (USPTO) notice of allowance for patent application number 14/083,135, entitled, "Analytical Method for Analyzing and Determining Impurities in Dianhydrogalactitol (VAL-083)". DelMar Pharmaceuticals Receives Notice of Allowance for Third US Patent for VAL-083
PR Newswire - Tue Jan 13, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar", "the Company"
today announced that the U.S. Patent and Trademark Office (USPTO) has issued a notice of allowance for patent application number 14/083,135, entitled, "Analytical Method for Analyzing and Determining Impurities in Dianhydrogalactitol (VAL-083)". DelMar Pharmaceuticals Provides Update on VAL-083 Clinical Trial and Outlines Corporate Objectives for 2015
PR Newswire - Mon Jan 12, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar", "the Company) provided an update on the Company's ongoing Phase I/II clinical trial with VAL-083 as a potential new treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. In addition, DelMar outlined its corporate objectives for 2015.
DelMar Pharmaceuticals Commences Offer to Exchange Common Stock for Outstanding Warrants
PR Newswire - Thu Jan 08, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company", "we" or "our"
today announced that it has commenced an offer to exchange ("Offer to Exchange" new shares of the Company's common stock ("Shares" for outstanding Company warrants to purchase up to 5,964,738 shares of common stock (the "Warrants" (at a ratio of one Share for every three Warrants tendered). In the event that all of the Warrants are exchanged, the Company shall issue 1,988,246 new shares of common stock. DelMar Pharmaceuticals to Present at Biotech Showcase(TM) 2015
PR Newswire - Wed Jan 07, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar", the "Company"
announced today that Jeffrey Bacha, DelMar's president & CEO, will be presenting at the Biotech Showcase(TM) 2015 Conference being held in San Francisco, CA. Key Growth Opportunities:KSA InterviewsDelmar Pharmaceutical,Critical Control Solutions Corp andCemtrex, Inc.
Marketwired - Wed Dec 17, 12:00PM CST
Delmar Pharmaceutical's (OTCQX: DMPI) CEO Jeff Bacha took time to update listeners on the company's lead compound, VAL-083 and it's clinical applications. He talked about how VAL-083 is able to penetrate the elusive blood brain barrier and therefore has potential in treating Glioblastoma in patients that have failed first and second-line therapy. He added that this molecule is also approved in China for the treatment of lung cancer so Delmar has also been generating new preclinical data to reposition the product. Mr. Bacha elaborated on the company's key goals for the next 12 months, the main one being to complete dose escalation and advance into a registration directed trial, which will position them to file for an approval with the FDA regarding refractory Glioblastoma.
CCZ.TO: 0.30 (-0.01)
DelMar Pharmaceuticals Joins OTCQX
PR Newswire - Tue Dec 02, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and "DelMar Pharma"
, a clinical stage drug development company focused on the development and commercialization of a new chemotherapy for the treatment of refractory glioblastoma multiforme (GBM), the most common and deadly form of human brain cancer, announced that it will begin trading today on the OTCQX® marketplace. OTC Markets Group Welcomes DelMar Pharmaceuticals to OTCQX®
PR Newswire - Tue Dec 02, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced DelMar Pharmaceuticals, Inc. (OTCQX: DMPI), a clinical and commercial stage drug development company, has qualified to trade on OTCQX®, the best marketplace for established, global and growth companies.
SeeThruEquity Issues Update on DelMar Pharmaceuticals Highlighting New Data on VAL-083
ACCESSWIRE - Thu Nov 20, 8:33AM CST
New York, NY / ACCESSWIRE / November 20, 2014 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments.
DelMar Pharmaceuticals' Promising New Data Support the Potential of VAL-083 to Meet Significant Unmet Medical Needs in the Treatment of Glioblastoma Multiforme
PR Newswire - Mon Nov 17, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma"
today announced the presentation of new data supporting the development of VAL-083 (dianhydrogalactitol), which is currently undergoing clinical development in the United States as a potential new chemotherapy for the treatment of refractory glioblastoma multiforme (GBM), the most common and deadly form of human brain cancer. DelMar Pharmaceuticals Presents Preclinical Data Supporting VAL-083 as a Potential New Treatment in Glioblastoma at the Society of Neuro-Oncology Annual Meeting
PR Newswire - Fri Nov 14, 10:45AM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma"
today announced the presentation of an abstract entitled, In vivo efficacy of VAL-083 in the treatment of MGMT-positive glioblastoma multiforme (GBM). DelMar Pharmaceuticals Announces September 30, 2014 Results and Provides Corporate Update
PR Newswire - Mon Nov 10, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the company"
today announced the filing of September 30, 2014 quarterly financial statements. DelMar Pharmaceuticals Invited to Present New Data on VAL-083 in the Treatment of Glioblastoma Multiforme at the Society for NeuroOncology Annual Meeting
PR Newswire - Thu Nov 06, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma"
today announced that the Company has been invited to present three separate abstracts at the 19th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology being held November 13 to 16 in Miami. The presentations will detail continued advancement and new understandings in the research and development of VAL-083, a potential new therapy for refractory glioblastoma multiforme (GBM), the most common and deadly form of brain cancer. The Life Sciences Report Interviews SeeThruEquity Regarding Microcap Life Sciences Companies
ACCESSWIRE - Wed Nov 05, 8:24AM CST
New York, NY / ACCESSWIRE / November 5, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it was recently interviewed by The Life Sciences Report regarding the microcap market for life sciences companies, during which SeeThruEquity analysts discussed DelMar Pharmaceuticals Inc. (OTCQB: DMPI), Manhattan Scientifics Inc. (OTCQB: MHTX) and TapImmune Inc. (OTCQB: TPIV).
VAL-083 Demonstrates Promise as a Potential Treatment for Non-small Cell Lung Cancer
PR Newswire - Thu Oct 09, 7:44AM CDT
DelMar Pharmaceuticals, Inc., (OTCQB: DMPI), a clinical-stage oncology company, today announced the presentation of promising new data supporting the activity of its lead drug compound, VAL-083, in the treatment of non-small cell lung cancer (NSCLC) at the AACR's New Horizons in Cancer Research: Harnessing Breakthroughs - Targeting Cures. The conference takes place October 9th to 12th in Pudong, Shanghai.
DelMar Pharmaceuticals Announces Presentations at Upcoming Scientific Meetings
PR Newswire - Mon Oct 06, 10:47AM CDT
DelMar Pharmaceuticals, Inc., (OTCQB: DMPI), a clinical-stage oncology company, today announced that the company has been invited to present new advancements at two upcoming peer reviewed scientific meetings.
